Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells NicOx it wants long-term studies on drug's cardiovascular and gastrointestinal safety, but no additional efficacy trials.
You may also be interested in...
Nicox PursuesTransformation Into Ophthalmic Specialty Company – And Partner
Nicox of France pins hopes on glaucoma drug Vesneo – targeted for FDA submission in second quarter 2015 – and recent purchase of Aciex Therapeutics to build itself into an international ophthalmic player and ‘partner of choice’ in Europe.
Vasopharm Raises $6.5 mill For Phase III-Ready Traumatic Brain Injury Therapy
The tiny German biotech, vasopharm, aims to maximize the attractiveness of its NO-synthase inhibitor for potential partners, and to keep the flag flying for nitric oxide research.
NicOx Kicks Off Specialty Ophthalmics Transformation With Altacor Buy
France's NicOx, aiming to transform into a specialty ophthalmology company after several late-stage disappointments, announced plans to acquire VC-backed U.K startup Altacor.